Piper Sandler Assumes Regeneron Pharmaceuticals at Overweight, Announces Price Target of $875

Benzinga Newsdesk www.benzinga.com Neutral 56.7%

Neg 0% Neu 56.7% Pos 0%

Piper Sandler analyst Biren Amin assumes Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight rating and announces Price Target of $875.